Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries

Probiotics and Antimicrobial Proteins

Volumn 3, Issue 2, 2011, Pages 68-96

  Pepperney, Adam ^a   Chikindas, Michael L ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Antimicrobial; Bacteriocins; Caries; Histatins; Mutacins; Peptides

Indexed keywords

ALPHA DEFENSIN; AMPHIBIAN PROTEIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERICIDE; BACTERIOCIN; BETA DEFENSIN 3; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; DHVAR 1; DHVAR 2; DHVAR 3; DHVAR 4; DHVAR 5; HISTATIN; HISTATIN 5; MERSACIDIN; MILK PROTEIN; MUTACIN; NEW DRUG; NISIN; PAC 113; PEPTIDE; PEPTIDOMIMETIC AGENT; POLYLYSINE; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL COLONIZATION; CANDIDIASIS; DENTAL CARE; DENTAL CARIES; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EUKARYOTE; HUMAN; MEMBRANE PERMEABILITY; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MOUTH CAVITY; NONHUMAN; PERIODONTAL DISEASE; PREVENTIVE DENTISTRY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; STREPTOCOCCUS MUTANS; TOOTH PLAQUE;

STREPTOCOCCUS MUTANS; STREPTOCOCCUS SOBRINUS;

EID: 79958773596     PISSN: 18671306     EISSN: 18671314     Source Type: Journal    
DOI: 10.1007/s12602-011-9076-5     Document Type: Review

References (247)

1. Abee T (1995) Pore-forming bacteriocins of gram-positive bacteria and self-protection mechanisms of producer organisms. FEMS Microbiol Lett 129: 1-10.
2. Anonymous (2010) NIH conensus statement on dental caries management. The American Dental Hygienists' Association (ADHA). Retrieved Oct 2, 2010, from http://www. adha. org/profissues/nih_consensus_statement. htm/.
3. Akesson M, Dufour M, Sloan GL, Simmonds RS (2007) Targeting of streptococci by zoocin A. FEMS Microbiol Lett 270: 155-161.
4. Alvarez DC, Perez VH, Justo OR (2006) Effect of the extremely low frequency magnetic field on nisin production by Lactococcus lactis subsp lactis using cheese whey permeate. Process Biochem 41: 1967-1973.
5. Anusavice KJ (2005) Present and future approaches for the control of caries. J Dent Educ 69: 538-554.
6. Aretz VL (1999) Ala(0)-actagardine, a new lantibiotic from cultures of Actinoplanes liguriae ATCC 31048. J Antibiot 52: 730-741.
7. Babasaki K, Takao T, Shimonishi Y, Kurahashi K (1985) Subtilosin A, a new antibiotic peptide produced by Bacillus subtilis 168: isolation, structural analysis, and biogenesis. J Biochem 98: 585-603.
8. Bajjar MB, Kashtanov D, Chikindas ML (2009) Natural antimicrobials e-Poly-l-lysine and nisin A for control of oral microflora. Probiotics and Antimicro Prot 1: 143-147.
9. Bals R, Wilson JM (2003) Cathelicidins-a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 60: 711-720.
10. Bender GR, Sutton SV, Marquis RE (1986) Acid tolerance, proton permeabilities, and membrane ATPases of oral streptococci. Infect Immunol 53: 331-338.
11. Bierbaum BH (1998) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother 42: 154-160.
12. Bierbaum G, Sahl H (2009) Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 10: 2-18.
13. ™. Retrieved Apr 5, 2011, from http://www. bioxhealthcare. com/.
14. Blackburn P, Goldstein BP, inventors; AMBI, Inc., assignee (1996) Nisin compositions to prevent the promotion of tooth decay by suppressing formation of acid from foods by oral bacteria. WIPO WO97/10801. 1996 Sep 19.
15. Bobek SH (2000) In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 44: 1485-1493.
16. Bretz WA LW (1987) Characteristics of trypsin-like activity in subgingival plaque samples. J Dent Res 66: 1668-1672.
17. Breukink WI (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276: 1772-1779.
18. Bush K (2004) Antibacterial drug discovery in the 21st century. Clin Microbiol Infect 10: 10-17.
19. Calderón-Santiago M, Luque DC (2009) The dual trend in histatins research. TrAC Trends Anal Chem 28: 1011-1018.
20. Campese M, Sun X, Bosch JA, Oppenheim FG, Helmerhorst EJ (2009) Concentration and fate of histatins and acidic proline-rich proteins in the oral environment. Arch Oral Biol 54: 345-353.
21. Casamassimo PS, Thikkurissy S, Edelstein BL (2009) Beyond the dmft the human and economic cost of early childhood caries. J Am Dent Assoc 140: 650-657.
22. Caufield PW, Cutter GR, Dasanayake AP (1993) Initial acquisition of mutans streptococci by infants: evidence for a discrete window of infectivity. J Dent Res 72: 37-45.
23. Caufield PM (1990) Preliminary characterization of four bacteriocins from Streptococcus mutans. Can J Microbiol 36: 123-130.
24. Shelburne CE, An FY, Dholpe V, Ramamoorthy A, Lopatin DE, Lantz MS (2007) The spectrum of antimicrobial activity of the bacteriocin subtilosin A. J Antimicrob Chemother 59: 297-300.
25. Chatterjee C, Paul M, Xie L (2005) Biosynthesis and mode of action of lantibiotics. Chem Rev 105: 633-683.
26. Chatterjee CS (1992) Mersacidin, a new antibiotic from Bacillus: in vitro and in vivo antibacterial activity. J Antibiot 45: 839-845.
27. Chen P, Novak J, Kirk M, Barnes S, Qi F, Caufield PW (1998) Structure-activity study of the lantibiotic mutacin II from Streptococcus mutans T8 by a gene. Appl Env Microbiol 64: 2335-2340.
28. Chikindas ML, Novak J, Caufield PW (1997) Microbially-produced peptides having potential application to the prevention of dental caries. Int J Antimicrob Agents 9: 95-105.
29. Chikindas ML, Novak J, Driessen AJM (1995) Mutacin-II, a bactericidal lantibiotic from Streptococcus mutans. Antimicrob Agents Chemother 39: 2656-2660.
30. Cirioni GA (2005) In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrob Agents Chemother 49: 1249-1252.
31. Concannon SP, Crowe TD, Abercrombie JJ, Molina CM, Hou P, Sukumaran DK, Raj PA, Leung KP (2003) Susceptibility of oral bacteria to an antimicrobial decapeptide. J Med Microbiol 52: 1083-1093.
32. Connor FD (2008) The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. Mol Microbiol 69: 218-230.
33. Cotter PD, Hill C, Ross RP (2005) Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Peptide Sci 6: 61-75.
34. ™. Retrieved Apr 5, 2011, from http://curaprox. gr/contents/.
35. Dagan FR (2000) Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J Biol Chem 275: 4230-4238.
36. Dahal N, Chaney N, Ellis D, Lu S, Smith L (2010) Optimization of the production of the lantibiotic mutacin 1140 in minimal media. Process Biochem 45: 1187-1191.
37. Dajani AS, Gray ED, Wannamaker LW (1970) Bactericidal substance from Staphylococcus aureus. Biological properties. J Exp Med 131: 1004-1015.
38. Dajani AS, Wannamaker L (1969) Demonstration of a bactericidal substance against beta-hemolytic streptococci in supernatant fluids of staphylococcal cultures. J Bacteriol 97: 985-991.
39. Dashper SG, Liu SW, Reynolds EC (2007) Antimicrobial peptides and their potential as oral therapeutic agents. Int J Pept Res Ther 13: 505-516.
40. Dashper SG, O'Brien-Simpson NM, Cross KJ, Paolini RA, Hoffmann B, Catmull DV, Malkoski M, Reynolds EC (2005) Divalent metal cations increase the activity of the antimicrobial peptide kappacin. Antimicrob Agents Chemother 49: 2322-2328.
41. de Kwaadsteniet M, Doeschate KT, Dicks LMT (2009) Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett Appl Microbiol 48: 65-70.
42. de Kwaadsteniet M, ten Doeschate K, Dicks LMT (2008) Characterization of the structural gene encoding nisin F, a new lantibiotic produced by a Lactococcus lactis subsp. lactis isolate from freshwater catfish (Clarias gariepinus). Appl Envl Microbiol 74: 547-549.
43. Delisle AL (1986) Properties of mutacin B, an antibacterial substance produced by Streptococcus mutans strain BHT. Microbios 46: 21-28.
44. Delisle AL (1976) Activity of two Streptococcus mutans bacteriocins in the presence of saliva, levan, and dextran. Infect Immun 13: 619-626.
45. Dong N, Faraj J, Capan Y, Leung K, DeLuca P (2007) Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. Pharm Res 24: 1544-1550.
46. Dorocka KK (2010) Susceptibility of Candida biofilms to histatin 5 and fluconazole. Anton Leeuw Int J G 97: 413-417.
47. Douglass CW, Day JM (1979) Cost and payment of dental services in the United States. J Dent Educ 43: 330-348.
48. Dowd KK (2004) Histatins: antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 56: 285-289.
49. Draper LA, Ross RP, Hill C (2008) Lantibiotic immunity. Curr Protein Peptide Sci 9: 39-49.
50. Eckert R, He J, Yarbrough DK, Qi F, Anderson MH, Shi W (2006) Targeted killing of Streptococcus mutans by a pheromone-guided "smart" antimicrobial peptide. Antimicrob Agents Chemother 50: 3651-3657.
51. Eto NE (2004) Oral streptococci exhibit diverse susceptibility to human beta-defensin-2: antimicrobial effects of hBD-2 on oral streptococci. Curr Microbiol 48: 85-87.
52. FDA. Federal Register (1998) Nisin preparation: affirmation of GRAS status as a direct human food ingredient. 21 CFR Part 184, federal register. 53: 11247-11251.
53. Featherstone JDB (2000) The science and practice of caries prevention. J Am Dent Assoc 131: 887-899.
54. Franz AH (2011) Diversity and applications of Bacillus bacteriocins. FEMS Microbiol Rev 35: 201-232.
55. Franzman MR, Burnell KK, Dehkordi-Vakil F, Guthmiller JM, Dawson DV, Brogden KA (2009) Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. Int J Antimicrob Agents 33: 14-20.
56. Fuchs PC, Barry AL, Brown SD (1998) In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother 42: 1213-1216.
57. Fukao YF (2008) Biosynthetic characterization and biochemical features of the third natural nisin variant, nisin Q, produced by Lactococcus lactis 61-14. J Appl Microbiol 105: 1982-1990.
58. Fukao ZT (2003) Identification of the lantibiotic Nisin Q, a new natural nisin variant produced by Lactococcus lactis 61-14 isolated from a river in Japan. Biosci Biotech Biochem 67: 1616-1619.
59. Fukushima FH (1982) Purification and chemical analysis of a bacteriocin from the oral bacterium Streptococcus mutans RM-10. Arch Oral Biol 27: 721-727.
60. Fukutani TY (1990) Characterization of leukocyte chemotactic activity of bacteriocin from Streptococcus mutans RM-10. Inflammation 14: 561-569.
61. Gargis SR, Heath HE, Heath LS (2009) Use of 4-sulfophenyl isothiocyanate labeling and mass spectrometry to determine the site of action of the streptococcolytic peptidoglycan hydrolase zoocin A. Appl Environ Microbiol 75: 72-77.
62. Ge YG, MacDonald DL, Holroyd KJ (1999) In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 43: 782-788.
63. Genco CA, Maloy WL, Kari UP (2003) Antimicrobial activity of magainin analogues against anaerobic oral pathogens. Int J Antimicrob Agents 21: 75-78.
64. Ghobrial OG, Derendorf H, Hillman JD (2009) Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 33: 70-74.
65. ™. Retrieved Apr 5, 2011, from http://www. biotene. com/.
66. Gobbo DR (2010) Porphyrin-apidaecin conjugate as a new broad spectrum antibacterial agent. ACS Med Chem Lett 1: 35-38.
67. Godballe T, Nilsson LL, Petersen PD, Jenssen H (2011) Antimicrobial β-peptides and α-peptoids. Chem Biol Drug Des 77: 107-116.
68. Gottler LM, Ramamoorthy A (2009) Structure, membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin. Biochim Biophys Acta Biomembr 1788: 1680-1686.
69. Gross E, Morell JL (1971) Structure of nisin. J Am Chem Soc 93: 4634-4635.
70. Hancock RE (2001) Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1: 156-164.
71. Hancock REW, Sahl H (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557.
72. Hancock REW (1997) Peptide antibiotics. Lancet 349: 418-422.
73. Hartman M, Martin A, Nuccio O, Catlin A (2010) Health spending growth at a historic low in 2008. Health Aff 29: 147-155.
74. Hasper SL (2008) Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry 47: 3308-3314.
75. Hay DI (1975) Fractionation of human parotid salivary proteins and the isolation of a histidine-rich acidic peptide which shows high affinity for hydroxyapatite surfaces. Arch Oral Biol 20: 553-558.
76. Hazlett L, Wu M (2011) Defensins in innate immunity. Cell Tiss Res 343: 175-188.
77. He ZG, Yuan CH, Zhang LW (2008) N-terminal acetylation in paenibacillin, a novel lantibiotic. FEBS Lett 582: 2787-2792.
78. He Z, Kisla D, Zhang L, Yuan C, Green-Church K, Yousef AE (2007) Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. App Env Microbiol 73: 168-178.
79. Helmerhorst EJ, Oppenheim FG (2007) Saliva: a dynamic proteome. J Dent Res 86: 680-693.
80. Helmerhorst EJ, Alagl AS, Siqueira WL (2006) Oral fluid proteolytic effects on histatin 5 structure and function. Arch Oral Biol 51: 1061-1070.
81. Helmerhorst EJ, Hodgson R, van't Hof W (1999) The effects of histatin-derived basic antimicrobial peptides on oral biofilms. J Dent Res 78: 1245-1250.
82. Helmerhorst EJ, van't Hof W, Veerman ECI (1997) Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem J 326: 39-45.
83. Helmerhorst EJ, Breeuwer P, van't Hof W, Walgreen-Weterings E, Oomen LC, Veerman EC, Amerongen AV, Abee T (1999) The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem 274: 7286-7291.
84. Helmerhorst EJ, Reijnders IM, van't Hof W, Veerman EC, Nieuw Amerongen AV (1999) A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides. FEBS Lett 449: 105-110.
85. Henzler Wildman KA, Lee D, Ramamoorthy A (2003) Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 42: 6545-6558.
86. Hill GM (1999) Lacticin 3147 displays activity in buffer against Gram-positive bacterial pathogens which appear insensitive in standard plate assays. Lett Appl Microbiol 28: 355-358.
87. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks TA, Crowley PJ, Hess M, Azizi A, Leung K, Cvitkovitch D, Bleiweis AS (1998) Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun 66: 2743-2749.
88. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van Der Weijden CC (2000) Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect Immun 68: 543-549.
89. Hillman JD, Johnson KP, Yaphe BI (1984) Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun 44: 141-144.
90. Hillman D, Orugunty R, Smith J, inventors; Oragenics, Inc., assignee (2009) Differentially protected orthogonal lantionine technology. United States patent US 7, 521, 529. 2009 Apr 21.
91. Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH (2007) Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J Appl Microbiol 102: 1209-1219.
92. Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF (2001) Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 147: 643-651.
93. Hong SY, Oh JE, Kwon M, Choi MJ, Lee JH, Lee BL, Moon HM, Lee KH (1998) Identification and characterization of novel antimicrobial decapeptides generated by combinatorial chemistry. Antimicrob Agents Chemother 42: 2534-2541.
94. Howell TH, Florellini JP, Blackburn P, Projan SJ, Harpe DI, Williams RC (1993) The effect of a mouthrinse based on nisin, a bacteriocin, on developing plaque and gingivitis in beagle dogs. J Clin Periodontol 20: 335-339.
95. Hultmark SH (1981) Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 292: 246-248.
96. Hyink O, Balakrishnan M, Tagg JR (2005) Streptococcus rattus strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol Lett 252: 235-241.
97. Ikeda T, Iwanami T, Hirasawa M, Watanabe C, McGhee JR, Shiota T (1982) Purification and certain properties of a bacteriocin from Streptococcus mutans. Infect Immun 35: 861-868.
98. Ikeda TK (1984) Mode of inhibitory action of a bacteriocin produced by Streptococcus mutans C3603. Infect Immun 44: 370-378.
99. Imanishi HS (1986) Isolation and mode of action of a cell-free bacteriocin (mutacin) from serotype g Streptococcus mutans MT3791. Zentralblatt fur Bakteriologie, Mikrobiologie, und hygiene-series A. Med Microbiol Infect Dis Virol Parasitol 261: 287-298.
100. Jack RW, Tagg JR, Ray B (1995) Bacteriocins of gram-positive bacteria. Microbiol Rev 59: 171-200.
101. Kawulka KE, Sprules T, Diaper CM, Whittal RM, McKay RT, Mercier P, Zuber P, Vederas JC (2004) Structure of subtilosin a, a cyclic antimicrobial peptide from Bacillus subtilis with unusual sulfur to α-carbon cross-links: formation and reduction. Biochemistry 43: 3385-3395.
102. Kelstrup FH (1985) Characterization and mode of action of a purified bacteriocin from the oral bacterium Streptococcus mutans RM-10. Arch Oral Biol 30: 229-234.
103. Kelstrup FH (1983) Isolation, partial purification and preliminary characterization of a bacteriocin from Streptococcus mutans RM-10. Anton Leeuw Int J G49: 41-50.
104. Kim HS, Park CB, Kim MS (1996) cDNA cloning and characterization of buforin I, an antimicrobial peptide: a cleavage product of histone H2A. Biochem Biophys Res Commun 229: 381-387.
105. Kirk NJ (1996) Detection of modified amino acids in lantibiotic peptide mutacin II by chemical derivatization and electrospray ionization mass spectroscopic analysis. Anal Biochem 236: 358-360.
106. Kirkup BC (2006) Bacteriocins as oral and gastrointestinal antibiotics: theoretical considerations, applied research, and practical applications. Curr Med Chem 13: 3335-3350.
107. Komatsuzawa H, Ouhara K, Kawai T, Yamada S, Fujiwara T, Shiba H, Kurihara H, Taubman MA, Sugai M (2007) Susceptibility of periodontopathogenic and cariogenic bacteria to defensins and potential therapeutic use of defensins in oral diseases. Curr Pharm Des 13: 3084-3095.
108. Komatsuzawa OK (2005) Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, beta-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 55: 888-896.
109. Koo SP, Bayer AS, Yeaman MR (2001) Diversity in antistaphylococcal mechanisms among membrane-targeting antimicrobial peptides. Infect Immun 69: 4916-4922.
110. Koulourides IT (1985) Anti-dental caries effect in rats and man of a bacteriocin purified from the oral bacterium Streptococcus mutans C3603. Arch Oral Biol 30: 381-384.
111. Kuramitsu HK (1993) Virulence factors of mutans streptococci-role of molecular genetics. Crit Rev Oral Bio Med 4: 159-176.
112. Kuramitsu YH (2005) Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob Agents Chemother 49: 541-548.
113. Laube BN (2007) Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicro Agents Chemother 51: 4125-4132.
114. Lavoie MH (1991) Effects of dietary carbohydrates on mutacin production and activity. Microbios 67: 35-46.
115. Lawton EM, Ross RP, Hill C, Cotter PD (2007) Two-peptide lantibiotics: a medical perspective. Mini-Rev Med Chem 7: 1236-1247.
116. Lawton EM, Cotter PD, Hill C, Ross RP (2007) Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol Lett 267: 64-71.
117. Lazzarini CF (2008) Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 15: 22-31.
118. Lecar EG (1977) Electrically gated ionic channels in lipid bilayers. Q Rev Biophys 10: 1-34.
119. Lee TS (2005) Membrane permeabilization, orientation, and antimicrobial mechanism of subtilosin A. Chem Phys Lipids 137: 38-51.
120. Leung KP, Abercrombie JJ, Campbell TM, Gilmore KD, Bell CA, Faraj JA, DeLuca PP (2009) Antimicrobial peptides for plaque control. Adv Dent Res 21: 57-62.
121. Leung KP, Crowe TD, Abercrombie JJ, Molina CM, Bradshaw CJ, Jensen CL, Luo Q, Thompson GA (2005) Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res 84: 1172-1177.
122. Li LN, Guo LH, Lux R (2010) Targeted antimicrobial therapy against Streptococcus mutans establishes protective non-cariogenic oral biofilms and reduces subsequent infection. Int Jour Oral Sci 2: 66-73.
123. Li XWS, Reddy MS, Baev D (2003) Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J Biol Chem 278: 28553-28561.
124. Liu X, Chung Y, Yang S, Yousef AE (2005) Continuous nisin production in laboratory media and whey permeate by immobilized Lactococcus lactis. Process Biochem 40: 13-24.
125. Loesche WJ, Loesche WJ (1986) Role of Streptococcus mutans in human dental decay. Microbiol Rev 50: 353-380.
126. Loesche WJ (1976) Chemotherapy of dental plaque infections. Oral Sci Rev 9: 63-107.
127. Loffet A (2002) Peptides as drugs: is there a market? J Pept Sci 8: 1-7.
128. Loyola-Rodriguez JP, Morisaki I, Kitamura K, Hamada S (1992) Purification and properties of extracellular mutacin, a bacteriocin from Streptococcus sobrinus. J Gen Microbiol 138: 269-274.
129. Macielag BK (2004) Taking inventory: antibacterial agents currently at or beyond Phase 1. Curr Opin Microbiol 7: 466-476.
130. Mackay BJ, Denepitiya L, Iacono VJ (1984) Growth-inhibitory and bactericidal effects of human-parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect Immun 44: 695-701.
131. Mah TF, O'Toole GA (2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9: 34-39.
132. Maisetta G, Batoni G, Esin S, Luperini F, Pardini M, Bottai D, Florio W, Giuca MR, Gabriele M, Campa M (2003) Activity of human beta-Defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother 47: 3349-3351.
133. Malkoski M, Dashper SG, O'Brien-Simpson NM, Talbo GH, Macris M, Cross KJ, Reynolds EC (2001) Kappacin, a novel antibacterial peptide from bovine milk. Antimicrob Agents Chemother 45: 2309-2315.
134. Margulis L (1996) Archaeal-eubacterial mergers in the origin of eukarya: phylogenetic classification of life. Proc Natl Acad Sci USA 93: 1071-1076.
135. Marsh PD (2004) Dental plaque as a microbial biofilm. Caries Res 38: 204-211.
136. Marsh PD (2003) Are dental diseases examples of ecological catastrophes? Microbiology 149: 279-294.
137. Martini SE (1988) Antimicrobial properties of peptides from Xenopus granular gland secretions. FEBS Lett 228: 337-340.
138. Marynka PY (2006) Acyl-substituted dermaseptin S4 derivatives with improved bactericidal properties, including on oral microflora. Antimicrob Agents Chemother 50: 4153-4160.
139. Maze JS (2004) Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 42: 1024-1029.
140. McClerren AL, Cooper LE, Quan C (2006) Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc Natl Acad Sci USA 103: 17243-17248.
141. McConville P; inventor; AMBI, Inc., assignee (1996) A chewing gum composition containing a bacteriocin antibacterial agent. WIPO WO 97/06772. 1996 Aug 19.
142. McConville P, Scott B, Mike P, inventors; AMBI, Inc., assignee (1996) Compositions containing nisin. WIPO WO 96/037181. 1996 May 22.
143. McKay MS, Olson E, Hesla MA, Panyutich A, Ganz T, Perkins S, Rossomando EF (1999) Immunomagnetic recovery of human neutrophil defensins from the human gingival crevice. Oral Microbiol Immunol 14: 190-193.
144. Metzger ZN (1995) The tetracyclic lantibiotic actagardine: 1H-NMR and 13C-NMR assignments and revised primary structure. Eur J Biochem 228: 786-797.
145. Mickels N, McManus C, Massaro J, Friden P, Braman V, D'Agostino R, Oppenheim F, Warbington M, Dibart S, van Dyke T (2001) Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis. J Clin Periodontol 28: 404-410.
146. Milenkovic PE (2010) Structural characterization and antimicrobial activity of the Zn(II) complex with P113 (Demegen), a derivative of histatin 5. Inorg Chem 49: 8690-8698.
147. Monsieurs DG (2004) Screening genomes of Gram-positive bacteria for double-glycine-motif containing peptides. Microbiology 150: 1121-1126.
148. Montville CJ (2001) Bacteriocins: safe, natural antimicrobials for food preservation. Int J Food Microbiol 71: 1-20.
149. Moore A (2003) The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep 4: 114-117.
150. Mor RS (2009) Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta Biomembr 1788: 1582-1592.
151. Morency HT (1995) Preliminary grouping of mutacins. Can J Microbiol 41: 826-831.
152. Morency H, Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC (2001) Comparison of the activity spectra against pathogens of bacterial strains producing a mutacin or a lantibiotic. Can J Microbiol 47: 322-331.
153. Mota-Meira M, Lacroix C, LaPointe G, Lavoie MC (1997) Purification and structure of mutacin B-Ny266: a new lantibiotic produced by Streptococcus mutans. FEBS Lett 410: 275-279.
154. Mota-Meira M, LaPointe G, Lacroix C, Lavoie MC (2000) MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob Agents Chemother 44: 24-29.
155. Mota-Meira M, Morency HLM (2005) In vivo activity of mutacin B-Ny266. J Antimicrob Chemother 56: 869-871.
156. Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP (2005) Chewing gum of antimicrobial decapeptide (KSL) as a sustained antiplaque agent: preformulation study. J Controlled Release 107: 122-130.
157. Nagasawa YT (2003) Epsilon-Poly-l-lysine: microbial production, biodegradation and application potential. Appl Microbiol Biotechnol 62: 21-26.
158. Navaratna MADB, Sahl HG, Tagg JR (1999) Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene. Infect Immun 67: 4268-4271.
159. Nguyen T, Zhang Z, Huang I, Wu C, Merritt J, Shi W, Qi F (2009) Genes involved in the repression of mutacin I production in Streptococcus mutans. Microbiology 155: 551-556.
160. Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK, Nuijens JH (2001) Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 69: 1469-1476.
161. Norberg S, O'Connor PM, Stanton C, Ross RP, Hill C, Fitzgerald GF, Cotter PD (2011) Altering the composition of caseicins A and B as a means of determining the contribution of specific residues to antimicrobial activity. Appl Env Microbiol 77: 2496-2501.
162. Novak J, Caufield PW, Miller EJ (1994) Isolation and biochemical characterization of a novel lantibiotic mutacin from Streptococcus mutans. J Bacteriol 176: 4316-4320.
163. Oman TJ, van der Donk WA (2009) Insights into the mode of action of the two-peptide lantibiotic Haloduracin. ACS Chem Biol 4: 865-874.
164. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner GD, Troxler RF (1988) Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 263: 7472-7477.
165. Oppenheim FG, Yang YC, Diamond RD, Hyslop D, Offner GD, Troxler RF (1986) The primary structure and functional characterization of the neutral histidine-rich polypeptide from human parotid secretion. J Biol Chem 261: 1177-1182.
166. ™. Retrieved Apr 5, 2011, from http://www. opushc. se/.
167. Oragenics Inc (2011) Retrieved Apr 3, 2011, from http://www. oragenics. com/.
168. Oren SY (2001) From "carpet" mechanism to de novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 22: 1629-1641.
169. Oudhoff MJ, Blaauboer ME, Nazmi K, Scheres N, Bolscher JGM, Veerman ECI (2010) The role of salivary histatin and the human cathelicidin LL-37 in wound healing and innate immunity. Biol Chem 391: 541-548.
170. Oudhoff MJ, Bolscher JGM, Nazmi K, Kalay H, van't Hof W, Amerongen AVN, Veerman ECI (2008) Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay. FASEB Journal 22: 3805-3812.
171. Pacgen Biopharmeceuticals Corporation (2011) PAC113. Retrieved Apr 5, 2011, from http://www. pacgenbiopharm. com/.
172. Paik SH, Chakicherla A, Hansen JN (1998) Identification and characterization of the structural and transporter genes for, and the chemical and biological properties of, Sublancin 168, a novel lantibiotic produced by Bacillus subtilis 168. J Biol Chem 273: 23134-23142.
173. Park CB, Kim HS, Kim SC (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244: 253-257.
174. Park CB, Kim MS, Kim SC (1996) A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem Biophys Res Commun 218: 408-413.
175. Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC (2000) Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci USA 97: 8245-8250.
176. Patel MM, inventor; WM Wrigley Jr Co., assignee (1995) Chewing gum products containing nisin and methods of preparation. WIPO WO 97/20473. 1995 Jan 12.
177. Payne JB, Iacono VJ, Crawford IT, Lepre BM, Bernzweig E, Grossbard BL (1991) Selective effects of histidine-rich polypeptides on the aggregation and viability of Streptococcus mutans and Streptococcus sanguis. Oral Microbiol Immunol 6: 169-176.
178. Peters BM, Zhu J, Fidel PL Jr, Scheper MA, Hackett W, El Shaye S, Jabra-Rizk M (2010) Protection of the oral mucosa by salivary histatin-5 against Candida albicans in an ex vivo murine model of oral infection. FEMS Yeast Res 10: 597-604.
179. Petersen PE (2003) The World Oral Health Report 2003: continuous improvement of oral health in the 21st century-the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol 31: 3-24.
180. Ploeg JR (2005) Regulation of bacteriocin production in Streptococcus mutans by the quorum-sensing system required for development of genetic competence. J Bacteriol 187: 3980-3989.
181. Pollock JJ, Denepitiya L, MacKay BJ, Iacono VJ (1984) Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun 44: 702-707.
182. Powers JP, Hancock RE (2003) The relationship between peptide structure and antibacterial activity. Peptides 24: 1681-1691.
183. Qi FX, Chen P, Caufield PW (2000) Purification and biochemical characterization of mutacin I from the group I strain of Streptococcus mutans, CH43, and genetic analysis of mutacin I biosynthesis genes. Appl Environ Microbiol 66: 3221-3229.
184. Qi F, Chen P, Caufield PW (2001) The Group I Strain of Streptococcus mutans, UA140, produces both the lantibiotic Mutacin I and a nonlantibiotic bacteriocin, Mutacin IV. Appl Env Microbiol 67: 15-21.
185. Qi F, Chen P (1999) Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Env Microbiol 65: 3880-3887.
186. Raj PA, Antonyraj KJ, Karunakaran T (2000) Large-scale synthesis and functional elements for the antimicrobial activity of defensins. Biochem J 347(Pt 3): 633-641.
187. Rennie J, Arnt L, Tang H, Nüsslein K, Tew GN (2005) Simple oligomers as antimicrobial peptide mimics. J Ind Microbiol Biotechnol 32: 296-300.
188. Robson CL, Wescombe PA, Klesse NA (2007) Isolation and partial characterization of the Streptococcus mutans type AII lantibiotic mutacin K8. Microbiology 153: t5-t41.
189. Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ (1995) Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Env Microbiol 61: 2873-2878.
190. Román Luque-Ortega J, van't Hof W, Veerman ECI, Saugar JM, Rivas L (2008) Human antimicrobial peptide histatin 5 is a cell-penetrating peptide targeting mitochondrial ATP synthesis in Leishmani. FASEB J 22: 1817-1828.
191. Ross AC, Vederas JC (2011) Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J Antibiot 64: 27-34.
192. Ross HM (2006) Casein-derived antimicrobial peptides generated by Lactobacillus acidophilus DPC6026. Appl Env Microbiol 72: 2260-2264.
193. Rothstein DM, Spacciapoli P, Tran LT, Xu T, Roberts FD, Dalla Serra M, Buxton DK, Oppenheim FG, Friden P (2001) Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Chemother 45: 1367-1373.
194. Ruissen ALA, Groenink J, Lommerse CH (2002) Effects of carbohydrate polymers applicable in saliva substitutes on the anti-Candida activity of a histatin-derived peptide. Arch Oral Biol 47: 749-756.
195. Ruissen GJ (2003) Degradation of antimicrobial histatin-variant peptides in Staphylococcus aureus and Streptococcus mutans. J Dent Res 82: 753-757.
196. Ryan MO (1998) Lacticin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl Env Microbiol 64: 439-445.
197. Ryan M, Rea M, Hill C, Ross R (1996) An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 62: 612-619.
198. Sajjan US, Tran LT, Sole N, Rovaldi C, Akiyama A, Friden PM, Forstner JF, Rothstein DM (2001) P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 45: 3437-3444.
199. Scheie AA (1994) Mechanisms of dental plaque formation. Adv Dent Res 8: 246-253.
200. Schmidt NW, Mishra A, Lai GH, Davis M, Sanders LK, Tran D, Garcia A, Tai KP, McCray PB, Ouellette AJ, Selsted ME, Wong GCL (2011) Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc 133: 6720-6727.
201. Schneider BT (2009) Influence of Ca2+ ions on the activity of lantibiotics containing a mersacidin-like lipid ii binding motif. Appl Environ Microbiol 75: 4427-4434.
202. Schroeder BJ, Wu Z, Buding S, Groscurth S, Marcinowski M, Beisner J, Buchner J, Schaller M, Strange EF, Wehkamp J (2011) Reduction of disulphide bonds unmask potent antimicrobial activity of human β-defensin 1. Nature 469: 419-423.
203. Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS (1992) Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem 267: 4292-4295.
204. Shai PN (2003) Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides 24: 1693-1703.
205. Shimotoyodome A, Kobayashi H, Tokimitsu I, Matsukubo T, Takaesu Y (2006) Statherin and histatin 1 reduce parotid saliva-promoted Streptococcus mutans strain MT8148 adhesion to hydroxyapatite surfaces. Caries Res 40: 403-411.
206. Simmonds RS, Naidoo J, Jones CL (1995) The streptococcal bacteriocin-like inhibitory substance, zoocin A, reduces the proportion of Streptococcus mutans in an artificial plaque. Microb Ecol Health Dis 8: 281-292.
207. Siqueira WL, Margolis HC, Helmerhorst EJ, Mendes FM, Oppenheim FG (2010) Evidence of intact histatins in the in vivo acquired enamel pellicle. J Dent Res 89: 626-630.
208. Skerlavaj RD (1988) Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils. J Biol Chem 263: 9573-9575.
209. Slade PD (1975) Production and properties of an extracellular bacteriocin from Streptococcus mutans bacteriocidal for group A and other streptococci. Infect Immun 12: 1375-1385.
210. Snyder OL (2005) Chimeric antimicrobial peptides exhibit multiple modes of action. Int J Pept Res Ther 11: 29-42.
211. Stallmann HP, Faber C, Bronckers ALJJ, de Blieck-Hogervorst JMA, Brouwer CPJM, Amerongen AVN, Wuisman PIJM (2005) Histatin and lactoferrin derived peptides: antimicrobial properties and effects on mammalian cells. Peptides 26: 2355-2359.
212. Steinberg AH (2006) In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J Antimicrob Chemother 58: 198-201.
213. Stevens KA, Sheldon BW, Klapes A (1991) Nisin treatment for inactivation of Salmonella species and other gram-negative bacteria. Appl Environ Microbiol 57: 3613-3615.
214. Sugishita MK (1998) Relationship of membrane curvature to the formation of pores by magainin 2. Biochemistry 37: 11856-11863.
215. Sugiyama K, Sugiyama K (1993) Anti-lipopolysaccharide activity of histatins, peptides from human saliva. Experientia 49: 1095-1097.
216. Sutyak KE, Wirawan RE, Aroutcheva AA, Chikindas ML (2008) Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. J Appl Microbiol 104: 1067-1074.
217. Tagg JR, Bannister LV (1979) "Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J Med Microbiol 12: 397-411.
218. Takeshita MY (1990) Inhibitory effects of synthetic histidine-rich peptides on haemagglutination by Bacteroides gingivalis 381. Arch Oral Biol 35: 775-777.
219. Tanzer JM, Livingston JTA (2001) The microbiology of primary dental caries in humans. J Dent Educ 65: 1028-1037.
220. Tao RC, Jurevic RJ, Coulton KK (2005) Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob Agents Chemother 49: 3883-3888.
221. Tew GN, Clements D, Tang H, Arnt L, Scott RW (2006) Antimicrobial activity of an abiotic host defense peptide mimic. Biochim Biophys Acta 1758: 1387-1392.
222. Thellade E (1986) The non-specific theory in microbial etiology of inflammatory periodontal diseases. J Clin Periodontol 13: 905-911.
223. Thomas LV, Wimpenny JWT (1996) Investigation of the effect of combined variations in temperature, pH, and NaCl concentration on nisin inhibition of Listeria monocytogenes and Staphylococcus aureus. Appl Environ Microbiol 62: 2006-2012.
224. Tong ZC, Dong LP, Zhou L (2010) Nisin inhibits dental caries-associated microorganism in vitro. Peptides 31: 2003-2008.
225. Travis GH (2001) Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease. Infect Immun 69: 1402-1408.
226. Troxler RF, Offner GD, Xu T, Vanderspek JC, Oppenheim FG (1990) Structural relationship between human salivary histatins. J Dent Res 69: 2-6.
227. van NA, Bolscher JGM, Veerman ECI (2004) Salivary proteins: protective and diagnostic value in cariology? Caries Res 38: 247-253.
228. Vargues T, Morrison GJ, Seo ES, Clarke DJ, Fielder HL, Bennani J, Pathania U, Kilanowski F, Dorin JR, Govan JRW, Mackay CL, Uhrín D, Campopiano DJ (2009) Efficient production of human β-Defensin 2 (HBD2) in Escherichia coli. Protein Pept Lett 16: 668-676.
229. Wade W (1999) Unculturable bacteria in oral biofilms. In: Newman HN, Wilson M (eds) Dental plaque revisited: oral biolfilms in health and diseases. BioLine, Cardiff, p 313.
230. Wade WG, Munson MA, de Lillo A, Weightman AJ (2005) Specificity of the oral microflora in dentinal caries, endodontic infections and periodontitis. Int Congr Ser 1284: 150-157.
231. Wang LY (2011) Effect of the antimicrobial decapeptide KSL on the growth of oral pathogens and Streptococcus mutans biofilm. Int J Antimicrob Agents 37: 33-38.
232. Wei GX, Campagna AN, Bobek LA (2006) Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J Antimicrob Chemother 57: 1100-1109.
233. Welling MM, Brouwer CP, van't Hof W W, Veerman EC, Amerongen AV (2007) Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo. Antimicro Agents Chemother 51: 3416-3419.
234. Wieprecht DM (1999) Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1462: 71-87.
235. Wierenga RR (2007) Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation. Appl Env Microbiol 73: 5809-5816.
236. Willey JM, van der Donk WA (2007) Lantibiotics: peptides of diverse structure and function. Annu Rev Microbiol 61: 477-501.
237. Wilson CN (2009) Rapid method for extracting the antibiotic mutacin 1140 from complex fermentation medium yeast extract. Can J Microbiol 55: 1261-1266.
238. Wirawan RE, Klesse NA, Jack RW, Tagg JR (2006) Molecular and genetic characterization of a novel nisin variant produced by Streptococcus uberis. Appl Env Microbiol 72: 1148-1156.
239. Yasufuku OT (1985) Effect of mutacin administration on Streptococcus mutans-induced dental caries in rats. Microbiol Immunol 29: 1163-1173.
240. Yeaman MR, Yount N (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55: 27-55.
241. Zachariah SL (2003) Structure and dynamics of the lantibiotic mutacin 1140. Biochemistry 42: 10372-10384.
242. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75: 39-48.
243. Zasloff M (1987) Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 84: 5449-5453.
244. Zasloff MD (1988) A two-dimensional NMR study of the antimicrobial peptide magainin 2. FEBS Lett 227: 21-26.
245. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
246. Zero DT, Fontana M, Martínez-Mier EA (2009) The biology, prevention, diagnosis, and treatment of dental caries. Scientific advances in the United States. J Am Dent Assoc 140: 25S-34S.
247. Zuo DJ (1995) Functional comparison of native and recombinant human salivary histatin 1. J Dent Res 74: 1837-1844.